Literature DB >> 31128261

Coexistence of schwannomatosis and glioblastoma in two families.

Caroline Deiller1, Julien Van-Gils2, Cécile Zordan1, Julie Tinat1, Hugues Loiseau3, Thierry Fabre4, Claire Delleci5, Joëlle Cohen6, Michel Vidaud7, Béatrice Parfait7, Cyril Goizet8.   

Abstract

Schwannomatosis is a rare affection predisposing to multiple peripheral neurologic tumors development. Approximatively, one third of patients with schwannomatosis are carriers of a germline mutation in LZTR1 (Leucin Zipper Transcription Regulator 1). Tumorigenesis in schwannomatosis responds to a somatic 5-hit/3-step mechanism resulting in a loss of function (LOF) of LZTR1 and the contiguous genes of locus 22q11.2q12.2. Effectively, LZTR1 is mapped on 22q11.2 and centromeric to SMARCB1 also implicated in the determinism of schwannomatosis and NF2, responsible for neurofibromatosis type 2. On a somatic point of view, LZTR1 mutations are known to drive with a significant frequency glioblastoma (GB) development. We report here two families in which segregate both multiple schwannomas and GB. In the first family, the proband received a diagnosis with of schwannomatosis after a surgery for a lumbar schwannoma at age 43, molecularly confirmed by identification of a germline heterozygous mutation in LZTR1. Her father, having unremarkable medical history deceased from an apparently isolated GB at age 59. In the second family, LZTR1-related schwannomatosis was diagnosed in the index case at age 70 after multiple schwannomas surgeries. Her elder sister had no neurological medical history before occurrence of a lethal GB at age 78. Molecular analysis of GB sample from both affected relatives showed the presence of the familial mutation. These observations hypothesize a potential link between schwannomatosis and the GB development. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Glioblastoma; LZTR1; Neurofibromatosis; SMARCB; Schwannomatosis

Mesh:

Substances:

Year:  2019        PMID: 31128261     DOI: 10.1016/j.ejmg.2019.103680

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore.

Authors:  Jerold Loh; Pei Yi Ong; Denise Li Meng Goh; Mark E Puhaindran; Balamurugan A Vellayappan; Samuel Guan Wei Ow; Gloria Chan; Soo-Chin Lee
Journal:  Hered Cancer Clin Pract       Date:  2022-06-13       Impact factor: 2.164

2.  Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients.

Authors:  Donatella Bianchessi; Maria Cristina Ibba; Veronica Saletti; Stefania Blasa; Tiziana Langella; Rosina Paterra; Giulia Anna Cagnoli; Giulia Melloni; Giulietta Scuvera; Federica Natacci; Claudia Cesaretti; Gaetano Finocchiaro; Marica Eoli
Journal:  Genes (Basel)       Date:  2020-06-19       Impact factor: 4.096

3.  Schwannomatosis Presenting With a Grade IV Glioblastoma: A Case Report and Literature Review.

Authors:  Nardine Abdelsayed; Zachary Bondranko; Peter Montesano
Journal:  Cureus       Date:  2022-03-22

4.  Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population.

Authors:  Fanxuan Deng; D Gareth Evans; Miriam J Smith
Journal:  Hum Mutat       Date:  2022-04-14       Impact factor: 4.700

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.